关于 Capivasertib(卡帕塞替尼) API
治疗类别 Oncology(肿瘤)

CAS 编号
1143532‑39‑1
API 技术
Small‑molecule synthetic API
剂型
片剂
Dr Reddy's 开发状态
开发中
Mechanism of action
Capivasertib inhibits all three AKT isoforms (AKT1, AKT2, AKT3).
AKT is a central signaling node in the PI3K/AKT/mTOR pathway, regulating cell proliferation, survival, and metabolism.
By blocking AKT kinase activity, capivasertib:
Inhibits phosphorylation of downstream AKT substrates
Suppresses tumor cell growth and survival
Overcomes resistance to endocrine therapy driven by PIK3CA mutations, AKT1 mutations, or PTEN loss
Demonstrates antitumor activity both as monotherapy and in combination with endocrine agents.
Indication
"Approved indication (FDA):
In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)‑positive, HER2‑negative, locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations, following disease progression on endocrine therapy."
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!